胸外科医师学会Intermacs 2022年度报告:聚焦2018年心脏移植分配系统
STS Intermacs第13次年度报告分析2012-2021年27314例连续流耐久性左心室辅助装置(LVAD)患者,2021年植入2464例,较2019年峰值下降23.5%,81.1%作为终点治疗,92.7%使用全磁悬浮装置,1年和5年生存率分别为83.0%和51.9%,卒中、消化道出血和再住院显著减少,2018年分配系统改变后3年移植比例从56.5%降至46.0%,带支持存活比例从24.1%升至38.1%。
要点
- 2021年LVAD植入量较2019年峰值下降23.5%,可能与COVID-19疫情及2018年心脏移植分配系统改变有关。
- 2021年81.1%患者以终点治疗为目的植入,92.7%使用全磁悬浮LVAD。
- 1年和5年生存率分别改善至83.0%和51.9%,卒中、消化道出血和再住院显著减少。
核心结论
- 尽管近年植入前临时循环支持更普遍且人群更老更重,LVAD患者1年和5年生存率仍持续改善,不良事件谱改善。
- 2018年心脏移植分配系统改变后,符合移植条件患者3年移植比例从56.5%降至46.0%,带支持存活比例从24.1%升至38.1%,凸显现有技术耐久性。
研究设计与样本
- STS Intermacs第13次年度报告,分析2012-2021十年间27314例接受连续流耐久性LVAD的患者。
- 2021年植入2464例原发LVAD,比较2017-2021年与2012-2016年两个时代。
- 采用竞争结局分析评估2018年心脏移植分配系统改变对LVAD候选资格、植入策略和结局的影响。
主要发现
- 2021年原发LVAD植入2464例,较2019年峰值年植入量下降23.5%。
- 2021年81.1%患者以终点治疗为目的植入,92.7%使用全磁悬浮LVAD。
- 1年和5年生存率分别为83.0%和51.9%。
- 卒中、消化道出血和再住院显著减少。
- 竞争结局分析中,符合移植条件患者3年移植比例从56.5%降至46.0%,带支持存活比例从24.1%升至38.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 13th annual report from The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) highlights outcomes for 27,314 patients receiving continuous-flow durable left ventricular assist devices (LVAD) during the last decade (2012-2021). In 2021, 2464 primary LVADs were implanted, representing a 23.5% reduction in the annual volume compared with peak implantation in 2019 and an ongoing trend from the prior year. This decline is likely a reflection of the untoward effects of the coronavirus disease 2019 pandemic and the change in the United States heart transplant allocation system in 2018. The last several years have been characterized by a shift in device indication and type, with 81.1% of patients now implanted as destination therapy and 92.7% receiving an LVAD with full magnetic levitation in 2021. However, despite an older, more ill population being increasingly supported preimplant with temporary circulatory devices in the recent (2017-2021) vs prior (2012-2016) eras, the 1- and 5-year survival continues to improve, at 83.0% and 51.9%, respectively. The adverse events profile has also improved, with a significant reduction in stroke, gastrointestinal bleeding, and hospital readmissions. Finally, we examined the impact of the change in the heart transplant allocation system in 2018 on LVAD candidacy, implant strategy, and outcomes. In the competing-outcomes analysis, the proportion of transplant-eligible patients receiving a transplant has declined from 56.5% to 46.0% at 3 years, whereas the proportion remaining alive with ongoing support has improved from 24.1% to 38.1% at 3 years, underscoring the durability of the currently available technology.
引用
- Yuzefpolskaya M, Schroeder SE, Houston BA, et al. The Society of Thoracic Surgeons Intermacs 2022 Annual Report: Focus on the 2018 Heart Transplant Allocation System. Ann Thorac Surg. 2022. PMID: 36462544. doi:10.1016/j.athoracsur.2022.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。